Literature DB >> 16210490

Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae.

Kathryn T Bieging1, Gowrisankar Rajam, Patricia Holder, Ross Udoff, George M Carlone, Sandra Romero-Steiner.   

Abstract

We developed fluorescent mono- and multivalent opsonophagocytic assays (fOPA and fmOPA, respectively) specific for seven Streptococcus pneumoniae serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F). Bacterial survival was quantitated with alamar blue, a fluorescent metabolic indicator. Both fOPA and fmOPA allow for determination of viability endpoints for up to seven serotypes with high levels of agreement to the reference method. The fmOPA eliminates colony counting, reduces serum volume, and produces results in 1 day.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16210490      PMCID： PMC1247838          DOI： 10.1128/CDLI.12.10.1238-1242.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  20 in total

1.  Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis.

Authors:  K T Mountzouros; A P Howell
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

2.  Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator.

Authors:  Sandra Romero-Steiner; Willie Spear; Nekeidra Brown; Patricia Holder; Thomas Hennessy; Patricia Gomez De Leon; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

Review 3.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

Authors:  Luis Jódar; Jay Butler; George Carlone; Ron Dagan; David Goldblatt; Helena Käyhty; Keith Klugman; Brian Plikaytis; George Siber; Robert Kohberger; Ih Chang; Thomas Cherian
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

4.  Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.

Authors:  F T Cutts; S M A Zaman; G Enwere; S Jaffar; O S Levine; J B Okoko; C Oluwalana; A Vaughan; S K Obaro; A Leach; K P McAdam; E Biney; M Saaka; U Onwuchekwa; F Yallop; N F Pierce; B M Greenwood; R A Adegbola
Journal:  Lancet       Date:  2005 Mar 26-Apr 1       Impact factor: 79.321

Review 5.  The pneumococcus: carriage, disease and conjugate vaccines.

Authors:  Steven Obaro; Richard Adegbola
Journal:  J Med Microbiol       Date:  2002-02       Impact factor: 2.472

6.  Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.

Authors:  Terhi Kilpi; Heidi Ahman; Jukka Jokinen; Kari S Lankinen; Arto Palmu; Heljä Savolainen; Marko Grönholm; Maija Leinonen; Tapani Hovi; Juhani Eskola; Helena Käyhty; Norman Bohidar; Jerald C Sadoff; P Helena Mäkelä
Journal:  Clin Infect Dis       Date:  2003-10-07       Impact factor: 9.079

7.  Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies.

Authors:  Kyung Hyo Kim; Jigui Yu; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

8.  Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.

Authors:  Steven B Black; Henry R Shinefield; Stella Ling; John Hansen; Bruce Fireman; David Spring; Jack Noyes; Edwin Lewis; Paula Ray; Janelle Lee; Jill Hackell
Journal:  Pediatr Infect Dis J       Date:  2002-09       Impact factor: 2.129

9.  Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae.

Authors:  Sandra Romero-Steiner; Carl Frasch; Nelydia Concepcion; David Goldblatt; Helena Käyhty; Merja Väkeväinen; Craig Laferriere; Dominique Wauters; Moon H Nahm; Mark F Schinsky; Brian D Plikaytis; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

10.  Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein--conjugated pneumococcal vaccine in Filipino infants.

Authors:  Maria Z Rosario Capeding; Taneli Puumalainen; Connie P Gepanayao; Helena Käyhty; Marilla G Lucero; Hanna Nohynek
Journal:  BMC Infect Dis       Date:  2003-08-10       Impact factor: 3.090
View more
  3 in total

Review 1.  Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.

Authors:  Sandra Romero-Steiner; Carl E Frasch; George Carlone; Roland A Fleck; David Goldblatt; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2006-02

2.  Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera.

Authors:  Charles E Rose; Sandra Romero-Steiner; Robert L Burton; George M Carlone; David Goldblatt; Moon H Nahm; Lindsey Ashton; Mitch Haston; Nina Ekström; Raili Haikala; Helena Käyhty; Isabelle Henckaerts; Nathalie Durant; Jan T Poolman; Phil Fernsten; Xinhong Yu; Branda T Hu; Kathrin U Jansen; Milan Blake; Elles R Simonetti; Peter W M Hermans; Brian D Plikaytis
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

Review 3.  Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.

Authors:  Shu Ki Tsoi; Pierre R Smeesters; Hannah R C Frost; Paul Licciardi; Andrew C Steer
Journal:  J Immunol Res       Date:  2015-05-25       Impact factor: 4.818
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.